Zenas Biopharma (NASDAQ:ZBIO – Get Free Report) is expected to announce its earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.92) per share for the quarter.
Zenas Biopharma Stock Performance
NASDAQ:ZBIO opened at $8.33 on Friday. Zenas Biopharma has a 52 week low of $5.83 and a 52 week high of $26.25. The stock has a market cap of $348.19 million and a P/E ratio of -2.35.
Analyst Ratings Changes
Several equities research analysts recently issued reports on the company. Guggenheim reiterated a “buy” rating and issued a $45.00 price target on shares of Zenas Biopharma in a research note on Wednesday, March 12th. Wedbush began coverage on Zenas Biopharma in a research report on Thursday. They set an “outperform” rating and a $35.00 target price for the company.
About Zenas Biopharma
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
See Also
- Five stocks we like better than Zenas Biopharma
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- Stock Analyst Ratings and Canadian Analyst Ratings
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- The Role Economic Reports Play in a Successful Investment Strategy
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Zenas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
